MoonLake: Sonelokimab Phase 3 Week 40 Shows 62% Response MoonLake reports 62% Week 40 clinical response for sonelokimab in Phase 3 VELA trials (Mar 28, 2026); full safety and endpoint details pending.

MoonLake: Sonelokimab Phase 3 Week 40 Shows 62% Response: MoonLake reports 62% Week 40 clinical response for sonelokimab in Phase 3 VELA trials (Mar 28, 2026); full safety and endpoint details pending. 👈 Read full analysis #MoonLake #Sonelokimab #ClinicalTrials #Phase3 #AADMeeting

Hagens Berman Reminds MoonLake Investors of Deadline for Lead Plaintiff in Class Action Lawsuit Hagens Berman alerts investors of the upcoming Lead Plaintiff deadline for the securities class action against MoonLake Immunotherapeutics, indicating potential legal options.

Hagens Berman Reminds MoonLake Investors of Deadline for Lead Plaintiff in Class Action Lawsuit #United_States #San_Francisco #Hagens_Berman #sonelokimab #MoonLake_Immunotherapeutics

MoonLake Immunotherapeutics Faces Class Action Suit After Troubling Phase 3 Trial Results for Sonelokimab Following severe Phase 3 trial results for Sonelokimab, MoonLake Immunotherapeutics faces a class action lawsuit from impacted investors amid allegations of misleading information.

MoonLake Immunotherapeutics Faces Class Action Suit After Troubling Phase 3 Trial Results for Sonelokimab #Phase_3_Trials #MoonLake #sonelokimab

MoonLake Immunotherapeutics Faces Class Action After Tumultuous Trial Results MoonLake Immunotherapeutics faces a class action lawsuit after revealing poor Phase 3 trial results for its product sonelokimab, impacting investors significantly.

MoonLake Immunotherapeutics Faces Class Action After Tumultuous Trial Results #United_States #San_Francisco #Hagens_Berman #sonelokimab #MoonLake_Immunotherapeutics

Berger Montague PC Initiates Class Action for MoonLake Immunotherapeutics Investors Following Disappointing Drug Trial Results A class action lawsuit against MoonLake Immunotherapeutics has been announced by Berger Montague PC, targeting investors affected by misleading drug efficacy claims.

Berger Montague PC Initiates Class Action for MoonLake Immunotherapeutics Investors Following Disappointing Drug Trial Results #USA #Philadelphia #Berger_Montague #sonelokimab #MoonLake_Immunotherapeutics

MoonLake Immunotherapeutics Faces Class Action Following Troubling Trial Data Release MoonLake Immunotherapeutics is facing a class action lawsuit after disappointing Phase 3 trial results for its skin disease treatment, sonelokimab.

MoonLake Immunotherapeutics Faces Class Action Following Troubling Trial Data Release #United_States #San_Francisco #Hagens_Berman #MoonLake #sonelokimab

MoonLake Immunotherapeutics Faces Investor Backlash Following Poor Phase 3 Trial Results MoonLake Immunotherapeutics experiences a dramatic drop in share price after announcing disappointing Phase 3 trial results for its key treatment.

MoonLake Immunotherapeutics Faces Investor Backlash Following Poor Phase 3 Trial Results #USA #San_Francisco #MoonLake #sonelokimab #VELA-2

MoonLake Immunotherapeutics Stock Drops 90% After Troubling Trial Results MoonLake Immunotherapeutics faces significant backlash from investors after a shocking 90% decline due to disappointing trial results for its lead drug, sonelokimab.

MoonLake Immunotherapeutics Stock Drops 90% After Troubling Trial Results #United_States #San_Francisco #MoonLake #sonelokimab #VELA-2